Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report

The spread of next-generation sequencing enables clinicians to identify rare oncogene alterations, including MET exon 14 skipping mutation, in clinical practice for NSCLC. Several tyrosine kinase inhibitors for MET exon 14 skipping mutation such as capmatinib and tepotinib have elucidated their effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ninomaru, Taira, Okada, Hideaki, Fujishima, Mika, Irie, Kei, Fukushima, Shoji, Hata, Akito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474417/
https://www.ncbi.nlm.nih.gov/pubmed/34590003
http://dx.doi.org/10.1016/j.jtocrr.2021.100145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474417/
https://www.ncbi.nlm.nih.gov/pubmed/34590003
http://dx.doi.org/10.1016/j.jtocrr.2021.100145

Ejemplares similares